Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update


- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) -

Excerpt from:
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Related Posts